Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660346 · ClinicalTrials.gov registry record · Phase 4
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
A Phase 4 study, sponsored by Sharp HealthCare.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02660346: Completed Phase 4 study, sponsored by Sharp HealthCare.
NCT02660346 is a Phase 4 study that has completed, run by Sharp HealthCare. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660346, a Phase 4 study, has completed, sponsored by Sharp HealthCare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality. It may also serve as biomarker for very early risk stratification. The aim of this study is to compare the outcomes for patients with elevated IL-10 levels (≥8 pg/ml) when treated with standard antibiotic therapy (daptomycin or vancomycin) versus early aggressive therapy (daptomycin with ceftaroline) for the treatment of MRSaB.
Primary Outcome
To determine whether or not early aggressive antibiotic therapy are correlated to shorter time to bacteremia clearance compared to standard therapy
Interventions
- DRUG Vancomycin
- DRUG Ceftaroline
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 4 |
What the finished NCT02660346 record still lists
NCT02660346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Vancomycin is the first listed.
NCT02660346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660346 about?
NCT02660346 is a clinical study titled "IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB". Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality. It may also serve as biomarker for very early risk stratification. The aim of this study is to compare the outcomes for pati...
What is the current status of trial NCT02660346?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-11. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT02660346?
The interventions under investigation include: Vancomycin (DRUG), Ceftaroline (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT02660346?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02660346's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia